Last reviewed · How we verify
Teclistamab (Tec)
Teclistamab is a bispecific antibody that redirects T cells to kill multiple myeloma cells by simultaneously binding CD3 on T cells and BCMA on myeloma cells.
Teclistamab is a bispecific antibody that redirects T cells to kill multiple myeloma cells by simultaneously binding CD3 on T cells and BCMA on myeloma cells. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | Teclistamab (Tec) |
|---|---|
| Also known as | JNJ-64007957 |
| Sponsor | University of Heidelberg Medical Center |
| Drug class | Bispecific T-cell engager (BiTE) |
| Target | CD3 and BCMA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Teclistamab functions as a T-cell engager that bridges cytotoxic T lymphocytes to B-cell maturation antigen (BCMA)-expressing myeloma cells, bringing them into close proximity to facilitate T-cell activation and tumor cell killing. This bispecific mechanism allows for potent anti-myeloma activity by leveraging the patient's own immune system. The drug has demonstrated efficacy in relapsed/refractory multiple myeloma patients, including those heavily pretreated with other therapies.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Cytokine release syndrome
- Infections
- Anemia
- Thrombocytopenia
- Fatigue
Key clinical trials
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (PHASE3)
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (PHASE3)
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (PHASE3)
- A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (PHASE2)
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (PHASE3)
- Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) (PHASE2)
- A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma (PHASE1, PHASE2)
- A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |